Evidence map›Paper›PMID 42079637›Full record

ReviewFrontiers in immunology2026

Trained immunity in lung injury and repair.

Thi Hong Nhung Pham, Bisheng Zhou

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thi Hong Nhung PhamDepartment of Pharmacology and Regenerative Medicine, University of Illinois College of Medicine, Chicago, IL, United States.
Bisheng ZhouDepartment of Pharmacology and Regenerative Medicine, University of Illinois College of Medicine, Chicago, IL, United States.

Funding

Perivascular macrophages - a new player in regulating endothelial repair following lung vascular injuryR01HL169447 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Bisheng Zhou · 2024 to 2026
$1.4M
Aerocyte-mediated Alveolar Epithelial Regeneration following Lung InjuryR01HL176717 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Bisheng Zhou · 2025 to 2026
$952k
NHLBI NIH HHS R01 HL169447NHLBI NIH HHS R01 HL176717
6 · The paper itself

Abstract

Trained immunity refers to a phenomenon in which innate immune cells undergo long-lasting functional adaptation following an initial challenge. This paradigm shift in pulmonary immunology reveals that classical innate cells such as alveolar macrophages and hematopoietic progenitors, as well as structural cells including epithelial and endothelial populations, can acquire memory-like traits through sustained epigenetic and metabolic reprogramming. In the lung, these reprogrammed circuits influence host defense, lung injury, repair, and fibrotic remodeling through mechanisms involving histone H3K4 trimethylation, mTOR-HIF-1α-dependent metabolic shifts, and KLF4-MERTK-driven efferocytosis. Recent studies highlight the dual nature of this response: whereas appropriately tuned training accelerates pathogen clearance and supports epithelial repair, excessive or persistent activation can exacerbate maladaptive inflammation and fibrosis. In this Mini-Review, we summarize advances from 2020 to 2025 on the cellular and molecular regulation of pulmonary trained immunity, its emerging roles in acute respiratory distress syndrome (ARDS) and lung fibrosis, and novel therapeutic approaches that aim to modulate innate immune reprogramming for lung repair.

Indexed as

Immunity, InnateLungLung InjuryTrained ImmunityAnimalsHumansKruppel-Like Factor 4Pulmonary FibrosisRespiratory Distress SyndromeKLF4 protein, humanKruppel-Like Factor 4ARDSinnate immune cellslung injury and repairmemorytrained immunity

Identifiers

PMID42079637
PMCPMC13132707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.